Klaria Pharma Holding AB (publ.) (KLAR.ST)
SEK 0.29
(-8.63%)
SEK 0.29
(-8.63%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 17.68 Million SEK | 5358.33% |
| 2022 | 324 Thousand SEK | -94.8% |
| 2021 | 6.23 Million SEK | 129.7% |
| 2020 | -20.98 Million SEK | -367.24% |
| 2019 | 7.85 Million SEK | 198.68% |
| 2018 | -7.95 Million SEK | 53.45% |
| 2017 | -17.09 Million SEK | 45.02% |
| 2016 | -31.1 Million SEK | 31.85% |
| 2015 | -45.63 Million SEK | -9182.02% |
| 2014 | -491.62 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -937 Thousand SEK | -105.3% |
| 2024 Q2 | -496 Thousand SEK | 47.07% |
| 2023 Q1 | -13.05 Million SEK | -4129.63% |
| 2023 Q2 | -8.86 Million SEK | 32.13% |
| 2023 Q3 | -2.28 Million SEK | 74.27% |
| 2023 Q4 | 17.68 Million SEK | 875.66% |
| 2023 FY | 17.68 Million SEK | 5358.33% |
| 2022 Q3 | -5.87 Million SEK | 8.74% |
| 2022 FY | 324 Thousand SEK | -94.8% |
| 2022 Q2 | -6.44 Million SEK | 70.92% |
| 2022 Q1 | -22.14 Million SEK | -455.24% |
| 2022 Q4 | 324 Thousand SEK | 105.51% |
| 2021 Q3 | -25.86 Million SEK | 34.83% |
| 2021 Q2 | -39.68 Million SEK | 17.71% |
| 2021 FY | 6.23 Million SEK | 129.7% |
| 2021 Q1 | -48.22 Million SEK | -129.78% |
| 2021 Q4 | 6.23 Million SEK | 124.1% |
| 2020 Q2 | -19.65 Million SEK | -20.51% |
| 2020 FY | -20.98 Million SEK | -367.24% |
| 2020 Q4 | -20.98 Million SEK | -9.56% |
| 2020 Q1 | -16.31 Million SEK | -307.7% |
| 2020 Q3 | -19.15 Million SEK | 2.55% |
| 2019 Q3 | -8.89 Million SEK | 38.41% |
| 2019 Q2 | -14.43 Million SEK | -65.75% |
| 2019 Q1 | -8.7 Million SEK | -9.42% |
| 2019 FY | 7.85 Million SEK | 198.68% |
| 2019 Q4 | 7.85 Million SEK | 188.35% |
| 2018 Q1 | -13.37 Million SEK | 21.79% |
| 2018 Q3 | -5.07 Million SEK | 39.07% |
| 2018 FY | -7.95 Million SEK | 53.45% |
| 2018 Q4 | -7.95 Million SEK | -56.86% |
| 2018 Q2 | -8.32 Million SEK | 37.73% |
| 2017 Q2 | -22.26 Million SEK | 21.73% |
| 2017 FY | -17.09 Million SEK | 45.02% |
| 2017 Q1 | -28.44 Million SEK | 8.53% |
| 2017 Q4 | -17.09 Million SEK | 18.06% |
| 2017 Q3 | -20.86 Million SEK | 6.28% |
| 2016 Q4 | -31.1 Million SEK | 8.0% |
| 2016 FY | -31.1 Million SEK | 31.85% |
| 2016 Q3 | -33.8 Million SEK | 9.56% |
| 2016 Q2 | -37.37 Million SEK | 10.82% |
| 2016 Q1 | -41.91 Million SEK | 8.15% |
| 2015 FY | -45.63 Million SEK | -9182.02% |
| 2015 Q3 | -48.44 Million SEK | 0.0% |
| 2015 Q4 | -45.63 Million SEK | 5.79% |
| 2014 FY | -491.62 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AcuCort AB | -19.24 Million SEK | 191.899% |
| AlzeCure Pharma AB (publ) | -29.1 Million SEK | 160.773% |
| BioGaia AB (publ) | -1.53 Billion SEK | 101.152% |
| Enzymatica AB (publ) | 17.73 Million SEK | 0.293% |
| Enorama Pharma AB (publ) | -5.71 Million SEK | 409.341% |
| Gabather AB (publ) | -1.11 Million SEK | 1686.099% |
| Moberg Pharma AB (publ) | -55.81 Million SEK | 131.683% |
| Nanexa AB (publ) | -61.13 Million SEK | 128.927% |
| Newbury Pharmaceuticals AB (publ) | -15.3 Million SEK | 215.566% |
| ODI Pharma AB | -2.63 Million SEK | 770.418% |
| Orexo AB (publ) | 302.8 Million SEK | 94.16% |
| Probi AB (publ) | -275.85 Million SEK | 106.411% |
| Swedencare AB (publ) | 1.42 Billion SEK | 98.756% |
| Swedish Orphan Biovitrum AB (publ) | 19.58 Billion SEK | 99.91% |
| Toleranzia AB | -17.45 Million SEK | 201.323% |
| Vivesto AB | -1.29 Million SEK | 1461.432% |